Literature DB >> 19443473

The case for fetal cardiac intervention.

H M Gardiner1.   

Abstract

Surgery for congenital heart disease is now often performed in the first months of life because mortality is higher and myocardial damage more serious in unoperated children or those undergoing delayed surgery. Fetal cardiac intervention may prove a logical extension and has been proposed for fetuses with critical semilunar valve stenosis or atresia. Early ventricular decompression may halt disease progression, alter the natural history and improve postnatal outcomes either by preserving a two-ventricle circulation or by improving the outlook for single-ventricle candidates because of a healthier myocardium and pulmonary bed. Without intervention, fetuses with a closed interatrial septum may develop circulatory failure resulting in hydrops and intrauterine death, whereas in utero balloon atrial septostomy may stabilise the situation and increase duration of pregnancy.

Entities:  

Mesh:

Year:  2009        PMID: 19443473     DOI: 10.1136/hrt.2007.138420

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  4 in total

1.  N-terminal pro-B-type natriuretic peptide in the circulation of fetuses with cardiac malformations.

Authors:  Waltraut M Merz; Kirsten Kübler; Eike Albers; Birgit Stoffel-Wagner; Ulrich Gembruch
Journal:  Clin Res Cardiol       Date:  2011-09-29       Impact factor: 5.460

Review 2.  The intersection of ethics and communication in prenatal imaging: challenges for the pediatric radiologist.

Authors:  Stephen D Brown
Journal:  Pediatr Radiol       Date:  2010-04

Review 3.  Fetal cardiac interventions: clinical and experimental research.

Authors:  Shi-Min Yuan; Gulimila Humuruola
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-05-10       Impact factor: 1.426

4.  Advances in the Prenatal Management of Fetal Cardiac Disease.

Authors:  Chetan Sharma; Joseph Burns; Krittika Joshi; Monesha Gupta; Harinder Singh; Arpit Agarwal
Journal:  Children (Basel)       Date:  2022-05-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.